DPAt a glance
Core facts about the doctor and the hospital, as provided by the hospital.
1 areaSpecialties: Hospital Ruber International · Grupo Quirónsalud
OncologyCategory
English, SpanishLanguages
JCIAccredited hospital · Madrid
US$940 from5 priced items
35 staffListed at this hospital
Dr. Javier Cortés is a Head of the Breast Unit, Instituto Oncológico Baselga at Grupo Quirónsalud in Madrid, Spain, a JCI-accredited center. Lists Hospital Ruber International · Grupo Quirónsalud. The hospital lists prices from US$940.
About
Medical oncology. Special training: breast cancer
International scientific associations:
International scientific associations:
- ESMO – European Society of Medical Oncology.
- ASCO – American Society of Medical Oncology.
- EORTC – European Organization for Research and Treatment of Cancer. Over
200 publications in journals, such as: the Lancet, the New England Journal of Medicine, the Annals of Oncology, the Journal of Clinical Oncology, and the Oncologist.
Title, journal, year of publication: Cortes J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, Seoane. J. New Approach to Cancer Therapy Based on a Molecularly Defined Cancer Classification. CA Cancer J Clin. 2014
Jan;64(1):70-4 F.I.: 162,500. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Scheneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J. Pertuzumab, Trastuzumab, Docetaxel
in HER2-Positive Metastatic Breast Cancer. New Eng J Med 2015 Feb 19;372(8):724-34
F.I.: 59,558.
Dr. Cortés participated in the following clinical trials that led to the development of targeted therapies in breast cancer: pertuzumab, everolimus, eribuline, evacizumab, abemaciclib, buparlisib, lapatinib, nintedanib.
Title, journal, year of publication: Cortes J, Calvo E, Vivancos A, Perez-Garcia J, Recio JA, Seoane. J. New Approach to Cancer Therapy Based on a Molecularly Defined Cancer Classification. CA Cancer J Clin. 2014
Jan;64(1):70-4 F.I.: 162,500. Swain SM, Baselga J, Kim SB, Ro J, Semiglazov V, Campone M, Ciruelos E, Ferrero JM, Scheneeweiss A, Heeson S, Clark E, Ross G, Benyunes MC, Cortes J. Pertuzumab, Trastuzumab, Docetaxel
in HER2-Positive Metastatic Breast Cancer. New Eng J Med 2015 Feb 19;372(8):724-34
F.I.: 59,558.
Dr. Cortés participated in the following clinical trials that led to the development of targeted therapies in breast cancer: pertuzumab, everolimus, eribuline, evacizumab, abemaciclib, buparlisib, lapatinib, nintedanib.
Ask the doctor's team about your case
Send your reports and questions to Grupo Quirónsalud. The hospital replies through Health-Tourism.com.
Free consultation • No obligation • Direct communication with the hospital
